omniture
logo
Search
RemeGen Co., Ltd
Media Room

Latest News

rss

On Rare Disease Day 2023 RemeGen Highlights Its Social Responsibility and Rare Disease Advocacy

YANTAI, China, Feb. 28, 2023 /PRNewswire/ -- RemeGen Co., Ltd.  ("RemeGen"...

2023-02-28 09:16 2766

RemeGen's RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA

YANTAI, China, Dec. 13, 2022 /PRNewswire/ -- RemeGen Co., Ltd.  ("RemeGen"...

2022-12-13 12:30 2250

RemeGen's Disitamab Vedotin Achieves First-Line Treatment Recommendation Status for Advanced Urothelial Cancer in Updated 2022 CSCO Guidelines

YANTAI, China, Nov. 17, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.H...

2022-11-17 08:00 3100

RemeGen Releases Phase II Clinical Study Data for Treatment of Myasthenia Gravis in Chinese Patients

YANTAI, China, Nov.1, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK,...

2022-11-01 12:12 2189

RemeGen Receives Orphan Drug Designation from FDA for Telitacicept for the Treatment of Myasthenia Gravis

YANTAI, China, Oct. 13, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.H...

2022-10-13 08:00 3413

RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemic Lupus Erythematosus (SLE) in China

YANTAI, China, Sept. 19, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995....

2022-09-19 21:00 1763

Biotech Company RemeGen Commemorates International Self-Care Day with Health Initiatives

YANTAI, China, July 25, 2022 /PRNewswire/ -- The 24th of July marks International Self Care Day, hi...

2022-07-25 11:00 2004

RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO Annual Meeting

YANTAI, China, May 23, 2022  /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK, SHA: 688331), a commercial...

2022-05-24 10:27 1970

RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome

YANTAI, China, Jan. 26, 2022 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotec...

2022-01-26 10:52 3305

RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome

YANTAI, China, Jan. 24, 2022 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotec...

2022-01-25 09:00 3266

RemeGen Reiterates Commitment to Its Battle Against Autoimmune Disease on World Strengthened Immunity Day 2021

YANTAI, China, Dec. 15, 2021 /PRNewswire/ -- To celebrate World Strengthened Immunity Day, RemeGen ...

2021-12-15 09:35 2618

RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug List for SLE and Gastric Cancer Treatment

YANTAI, China, Dec. 3, 2021 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotech...

2021-12-03 13:45 3713
12